{"id":48,"date":"2008-08-28T15:50:29","date_gmt":"2008-08-28T19:50:29","guid":{"rendered":"https:\/\/www.bumc.bu.edu\/endo\/research\/diabetes\/"},"modified":"2021-06-07T12:57:10","modified_gmt":"2021-06-07T16:57:10","slug":"diabetes","status":"publish","type":"page","link":"https:\/\/www.bumc.bu.edu\/endo\/research\/diabetes\/","title":{"rendered":"Diabetes Research"},"content":{"rendered":"

The diabetes research unit is composed of an interdisciplinary team engaged in basic, translational and clinical diabetes research.\u00a0Research interests of our team include: <\/span><\/strong>diabetes types 1 and 2, atypical diabetes, MODY, inpatient diabetes management, and diabetes pathophysiology and the role of T cells.\u00a0To learn about individual research interests, please click on the faculty member’s name to be taken to their profile. You can also find a list of their publications there.<\/p>\n

Our Research Team<\/h3>\n

Clinical Investigators<\/em><\/h4>\n

Sara Alexanian, MD<\/a>
\nKatie Modzelewski, MD<\/a>
\nDevin Steenkamp, MBChB<\/a>
\nCatherine Sullivan, MD<\/a>
\nKathryn Fantasia, MD<\/a><\/p>\n

Basic Science Investigators<\/em><\/h4>\n

Barbara Corkey, PhD<\/a>
\nJude Deeney, PhD<\/a>
\nHans Dooms, PhD<\/a><\/p>\n

Research Support Staff<\/em><\/h4>\n

\u00d6zden \u00d6zkur Akinci – Research Study Coordinator
\nZhihui Ju, MSPH – Research Study Coordinator<\/p>\n

Current Studies (Now Recruiting!) <\/span><\/h2>\n

\"\"<\/a><\/p>\n

Do you have type 2 diabetes?<\/strong><\/p>\n

Do you want to:
\n\u2022 Take a more active role in managing your diabetes?
\n\u2022 Get regular expert medical care to ensure that your blood sugar is well-controlled?
\n\u2022 Receive free regular eye examinations to ensure optimal standard of care?
\n\u2022 Help others by contributing to medical research?<\/p>\n

If so, why not take part in our clinical study? FOCUS is currently recruiting.<\/p>\n

The FOCUS study<\/strong>: FOCUS is a clinical study looking into the long-term effect of a new medicine called “semaglutide” on diabetic eye disease in people with type 2 diabetes.<\/p>\n

You may qualify to participate in FOCUS if you:
\n\u2022 Are over 18 years of age
\n\u2022 Have had type 2 diabetes for 10 years or more
\n\u2022 have high blood sugar levels<\/p>\n

Participating in this study will not affect the care you receive at Boston Medical Center. To find out if you may qualify for this study, please take this brief screening questionnaire<\/a>. If you have questions or would prefer to complete the screening questionnaire over the phone, please call Zhihui Ju at 617.414.2951 or send her an email here<\/a>.<\/p>\n

The ENDO (Endocrinology, Nutrition, and Diabetes Opportunities) Registry<\/strong>: We are currently creating a registry of interested individuals who would like to participate in research at Boston Medical Center or Boston University School of Medicine. The option to join the registry is voluntary. Joining will not affect the care you receive at Boston Medical Center. For more information, please read the ENDO Registry Consent Form<\/a>. To enroll in the registry, please go to https:\/\/is.gd\/ENDOregistry<\/a>. If you have questions prior to enrolling, please email<\/a> or call 617.414.2951 or 617.414.2935.<\/p>\n

Estamos creando un registro de individuos interesados en participar en estudios de investigaci\u00f3n en Boston Medical Center o Boston University School of Medicine. Participar en el registro es voluntario. Participar no afectar\u00e1 la atenci\u00f3n recibida en Boston Medical Center. Para m\u00e1s informaci\u00f3n, por favor leer el formulario de consentimiento. Para inscribirse en el registro, por favor ingresar a https:\/\/is.gd\/ENDOregistry_Spanish<\/a>.<\/p>\n

\"ENDO<\/a>
\n+++<\/span><\/p>\n

<\/h2>\n

Ongoing Studies (Closed to Enrollment)<\/span><\/h2>\n

Ongoing Research Studies\"GAZELLE<\/em><\/h4>\n

GAZELLE Trial (Mylan)<\/strong>: If you are an adult between ages 18 and 65 living with type 1 diabetes you may be eligible to take part in the GAZELLE clinical research trial. This trial\u00a0will look at an investigational fast-acting insulin to see if it works as effectively as an existing fast-acting insulin already being used to treat diabetes. Trial-related medications, procedures, equipment and supplies will be provided at no cost; health insurance is not required to participate.<\/p>\n

SWITCH PRO (Novo Nordisk)<\/strong>: This clinical trial is comparing the effect of insulin degludec and insulin glargine. Participants will first go through a 4-week screening and run-in period.\u00a0If\u00a0eligible to continue in the study, participants will be treated with insulin degludec\u00a0(100 U\/mL) and insulin glargine (100 U\/mL) during two different periods each of 18\u00a0weeks duration. Both medicines are approved for use in humans and available on the market.\u00a0In order to evaluate\u00a0 changes in blood sugar level over time while being treated\u00a0with the two different insulins, participants will be asked to wear a small blood sugar sensor\u00a0on the back of their upper arm 3 times during the study.<\/p>\n

\"Switch<\/p>\n

Past Research Studies (Click to Expand)<\/em><\/h4>
<\/p>\n

INSTRIDE 4 (Mylan): <\/strong>The INSTRIDE 4 Study looked at the ways the investigational insulin works to control blood sugar levels in patients with Type 1 Diabetes and to check how safe they are. All participants in this study received the potentially long-acting investigational medication, in addition to an FDA-approved, rapid-acting insulin at mealtimes. Approximately 200 people participated in this study internationally. The study was about 26 weeks (6 months) long.<\/p>\n

PIONEER 2 (Novo Nordisk)<\/strong>: Boston Medical Center was one of hundreds of sites to conduct the second phase 3a trial with oral semaglutide for treatment of adults with type 2 diabetes. Oral semaglutide is a new GLP-1 analogue taken once daily as a tablet. The 52-week, open label trial investigated the efficacy and safety of 14 mg oral semaglutide compared with 25 mg empagliflozin in 816 people with type 2 diabetes, inadequately controlled on metformin. The confirmatory endpoints were defined after 26 weeks of treatment. Read their full results announcement here<\/a>.<\/p>\n

Linagliptin Inpatient Trial<\/strong> \u2013 A Randomized Controlled Trial on the Safety and Efficacy of Linagliptin (Tradjenta\u00ae) Therapy for the Inpatient Management of General Surgery Patients with Type 2 Diabetes: This study compared linagliptin (a once-daily diabetes pill) plus as-needed rapid insulin shots vs. long acting insulin glargine plus scheduled rapid insulin shots for the treatment of diabetes patients after they have surgery. Approximately 280 participants from 4 United States medical centers participated.<\/p>\n

Linagliptin Outpatient Trial<\/strong> \u2013 The safety and efficacy of Linagliptin (Tradjenta) therapy for an A1c directed post-discharge management algorithm of general surgery patients with type 2 diabetes: Only thos individuals who completed the Linagliptin Inpatient Trial were invited to participate in this extended study. This study compared the effect of Linagliptin (diabetes pill) with insulin shots for the treatment of diabetes after participants left the hospital.<\/p>\n

Technology usage among patients receiving care in the Center for Endocrinology, Diabetes, Nutrition and Weight Managemen<\/strong>t: The purpose of this survey was to characterize the patient population of the BMC Endocrinology, Diabetes, Nutrition and Weight Management Clinic. We sought to dispel myths about technology access and usage among our patients. The survey was adapted from Pew Research Center\u2019s technology questionnaire and their data. The survey contained questions about internet usage, device ownership, preferred communication methods, use of technology for health, social media usage, and optional demographic information.<\/div>\n<\/div>\n\n

Patients and visitors:<\/em>\u00a0<\/span><\/strong><\/span>If you are interested in hearing about studies that you may be able to participate in, please consider enrolling in the ENDO Registry<\/a>. Alternatively, you may also\u00a0<\/span>email<\/a> or call 617.414-2935 or 617-414-2951 .<\/p>\n","protected":false},"excerpt":{"rendered":"

The diabetes research unit is composed of an interdisciplinary team engaged in basic, translational and clinical diabetes research.\u00a0Research interests of our team include: diabetes types 1 and 2, atypical diabetes, MODY, inpatient diabetes management, and diabetes pathophysiology and the role of T cells.\u00a0To learn about individual research interests, please click on the faculty member’s name […]<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":46,"menu_order":1,"comment_status":"closed","ping_status":"closed","template":"page-templates\/no-sidebars.php","meta":[],"_links":{"self":[{"href":"https:\/\/www.bumc.bu.edu\/endo\/wp-json\/wp\/v2\/pages\/48"}],"collection":[{"href":"https:\/\/www.bumc.bu.edu\/endo\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.bumc.bu.edu\/endo\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.bumc.bu.edu\/endo\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.bumc.bu.edu\/endo\/wp-json\/wp\/v2\/comments?post=48"}],"version-history":[{"count":38,"href":"https:\/\/www.bumc.bu.edu\/endo\/wp-json\/wp\/v2\/pages\/48\/revisions"}],"predecessor-version":[{"id":1809,"href":"https:\/\/www.bumc.bu.edu\/endo\/wp-json\/wp\/v2\/pages\/48\/revisions\/1809"}],"up":[{"embeddable":true,"href":"https:\/\/www.bumc.bu.edu\/endo\/wp-json\/wp\/v2\/pages\/46"}],"wp:attachment":[{"href":"https:\/\/www.bumc.bu.edu\/endo\/wp-json\/wp\/v2\/media?parent=48"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}